Compare Motorola Solutions Inc (MSI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Motorola Solutions Inc trades at $463.3 (market cap $76.62B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Motorola Solutions Inc pays a 1.05% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MSI | VRTX | |
|---|---|---|
Market Cap | $76.62B | $134.06B |
Sector | Technology | Health |
52-Week High | $491.24 | $557.96 |
52-Week Low | $363.83 | $376.62 |
Enterprise Value | $85.53B | $128.18B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $462.98, down 1.08% today, with strong technical support at $459 and bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $4.41 vs. $3.85, revenue growth to $11.68B in 2025, and a $2B share repurchase authorization announced September 2026. Recent acquisition of D-Fend Solutions for $1.5B expands counter-drone capabilities.
Outlook remains positive with 70.6% analyst buy ratings and $536.50 consensus price target, representing 16% upside. Risks include elevated valuation multiples (P/E 36.48) and significant capital expenditures driving negative cash flow. The stock offers growth potential through security technology expansion but faces execution risks from recent acquisitions and competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
